152 related articles for article (PubMed ID: 20935058)
1. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.
Giralt SA; Mangan KF; Maziarz RT; Bubalo JS; Beveridge R; Hurd DD; Mendoza FL; Rubenstein EB; DeGroot TJ; Schuster MW
Ann Oncol; 2011 Apr; 22(4):939-946. PubMed ID: 20935058
[TBL] [Abstract][Full Text] [Related]
2. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
3. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
Rozzi A; Nardoni C; Corona M; Restuccia MR; Fabi A; Bria E; Minniti G; Lanzetta G
Support Care Cancer; 2011 May; 19(5):697-701. PubMed ID: 20467757
[TBL] [Abstract][Full Text] [Related]
4. Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study.
Isoda A; Saito R; Komatsu F; Negishi Y; Oosawa N; Ishikawa T; Miyazawa Y; Matsumoto M; Sawamura M; Manaka A
Int J Hematol; 2017 Apr; 105(4):478-484. PubMed ID: 27873176
[TBL] [Abstract][Full Text] [Related]
5. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T
Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220
[TBL] [Abstract][Full Text] [Related]
6. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience.
Loteta B; Paviglianiti A; Naso V; Ferreri A; Moscato T; Console G; Canale FA; Irrera G; Pugliese M; Di Costanzo A; Provenzano PF; Loddo V; Porto G; Cusumano G; Russo L; Meliambro N; Romeo V; Porcino D; Gallo S; Gangemi T; Rossetti AM; Martino M
Support Care Cancer; 2022 Jan; 30(1):585-591. PubMed ID: 34347181
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
Aapro M; Fabi A; Nolè F; Medici M; Steger G; Bachmann C; Roncoroni S; Roila F
Ann Oncol; 2010 May; 21(5):1083-8. PubMed ID: 20080830
[TBL] [Abstract][Full Text] [Related]
8. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials.
Celio L; Bonizzoni E; Bajetta E; Sebastiani S; Perrone T; Aapro MS
Support Care Cancer; 2013 Feb; 21(2):565-73. PubMed ID: 22869054
[TBL] [Abstract][Full Text] [Related]
9. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
Einhorn LH; Brames MJ; Dreicer R; Nichols CR; Cullen MT; Bubalo J
Support Care Cancer; 2007 Nov; 15(11):1293-1300. PubMed ID: 17436025
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy.
Maemondo M; Masuda N; Sekine I; Kubota K; Segawa Y; Shibuya M; Imamura F; Katakami N; Hida T; Takeo S;
Ann Oncol; 2009 Nov; 20(11):1860-6. PubMed ID: 19561037
[TBL] [Abstract][Full Text] [Related]
11. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
Gralla RJ; Bosnjak SM; Hontsa A; Balser C; Rizzi G; Rossi G; Borroni ME; Jordan K
Ann Oncol; 2014 Jul; 25(7):1333-1339. PubMed ID: 24631949
[TBL] [Abstract][Full Text] [Related]
12. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
13. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).
Karthaus M; Tibor C; Lorusso V; Singh-Arora R; Filippov A; Rizzi G; Borroni ME; Rossi G; Grunberg SM
Support Care Cancer; 2015 Oct; 23(10):2917-23. PubMed ID: 25724407
[TBL] [Abstract][Full Text] [Related]
15. Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study.
Deauna-Limayo D; Aljitawi OS; Ganguly S; Abhyankar S; Wick JA; McGuirk JP
J Oncol Pharm Pract; 2014 Aug; 20(4):263-9. PubMed ID: 24005093
[TBL] [Abstract][Full Text] [Related]
16. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Aapro MS; Grunberg SM; Manikhas GM; Olivares G; Suarez T; Tjulandin SA; Bertoli LF; Yunus F; Morrica B; Lordick F; Macciocchi A
Ann Oncol; 2006 Sep; 17(9):1441-9. PubMed ID: 16766588
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
Maeda A; Ura T; Asano C; Haegawa I; Nomura M; Komori A; Narita Y; Taniguchi H; Kadowaki S; Muro K; Horio Y; Yoshida T; Oze I; Kajita M; Mizutani A
Asia Pac J Clin Oncol; 2016 Sep; 12(3):254-8. PubMed ID: 27030364
[TBL] [Abstract][Full Text] [Related]
18. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial.
Schmitt T; Goldschmidt H; Neben K; Freiberger A; Hüsing J; Gronkowski M; Thalheimer M; Pelzl le H; Mikus G; Burhenne J; Ho AD; Egerer G
J Clin Oncol; 2014 Oct; 32(30):3413-20. PubMed ID: 25225424
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
Eisenberg P; MacKintosh FR; Ritch P; Cornett PA; Macciocchi A
Ann Oncol; 2004 Feb; 15(2):330-7. PubMed ID: 14760130
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]